乳腺癌作為女性第一常見的惡性腫瘤，嚴重影響女性患者的生存質(zhì)量。血管內(nèi)皮生長因子（VEGF）已被確定為誘導(dǎo)腫瘤血管生成的關(guān)鍵因子，目前已有研究較多的用于乳腺癌治療的抗VEGF靶向藥物。另一方面，免疫療法的出現(xiàn)是惡性腫瘤治療的重大突破?？剐律苄纬伤幬锱c免疫療法在針對乳腺癌的治療方案中不失為一種合理的選擇?？偨Y(jié)了抗VEGF靶向藥物聯(lián)合免疫檢查點抑制劑、腫瘤疫苗、治療性抗體在乳腺癌治療中的研究進展。

Breast cancer, as the first common malignant tumor in women, seriously affects the quality of life of female patients. Vascular endothelial growth factor (VEGF) has been identified as the key factor to induce tumor angiogenesis. At present, there are many anti-VEGF-targeted drugs for the treatment of breast cancer. On the other hand, the emergence of immunotherapy is a major breakthrough in the treatment of malignant tumors. Anti-angiogenesis drugs and immunotherapy are a reasonable choice in treatment of breast cancer. This article summarized the research progress of anti-VEGF-targeted drugs combined with immune checkpoint inhibitors, tumor vaccines, therapeutic antibodies in the treatment of breast cancer.

R979.1

四川省科技計劃項目(2023YFS0473)